Tissue microarrays as a tool in the discovery and validation of tumor markers.

Tissue microarrays are a platform of condensed histopathology that has revolutionized the translation of basic science to clinical utility. Tissue microarrays have resulted in a paradigm shift from histopathology to immunopathology and moved analysis of small selected samples sets of tens of specimens to a high-throughput environment of hundreds of specimens. Tissue microarrays have influenced validation strategies, but have a role in discovery as well, allowing a pathways approach to analysis of tumors.

[1]  Gallya Gannot,et al.  Evaluation of non-formalin tissue fixation for molecular profiling studies. , 2002, The American journal of pathology.

[2]  S. Hewitt,et al.  Promises and challenges of predictive tissue biomarkers. , 2007, Biomarkers in medicine.

[3]  William C Reinhold,et al.  Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. , 2003, Cancer research.

[4]  Clive R Taylor,et al.  Recommendations for Improved Standardization of Immunohistochemistry , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  V. Sondak,et al.  Markers and tissue resources for melanoma: meeting report. , 2006, Cancer research.

[6]  S. Hewitt.  Design, construction, and use of tissue microarrays. , 2004, Methods in molecular biology.

[7]  Stephen M Hewitt,et al.  The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis , 2004, Nature Medicine.

[8]  C. Moskaluk,et al.  Tissues from population-based cancer registries: a novel approach to increasing research potential. , 2005, Human pathology.

[9]  Stephen M Hewitt,et al.  The application of tissue microarrays in the validation of microarray results. , 2006, Methods in enzymology.

[10]  Stephen M Hewitt,et al.  Tissue microarrays enabling high-throughput molecular pathology. , 2007, Current opinion in biotechnology.

[11]  S. Hewitt,et al.  Infrared spectroscopic imaging for histopathologic recognition , 2005, Nature Biotechnology.

[12]  D. Slamon,et al.  Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. , 2001, The American journal of pathology.

[13]  Stephen M Hewitt,et al.  Tissue microarrays: bridging the gap between research and the clinic , 2005, Expert review of proteomics.

[14]  S. Hewitt,et al.  Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of β-catenin in ovarian tumours , 2006, British Journal of Cancer.

[15]  Carlos Caldas,et al.  A Recurrent Chromosome Breakpoint in Breast Cancer at the NRG1/Neuregulin 1/Heregulin Gene , 2004, Cancer Research.

[16]  Stephen M. Hewitt,et al.  Post-analysis follow-up and validation of microarray experiments , 2002, Nature Genetics.

[17]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[18]  Sebastian Brenner,et al.  NAD(P)H Oxidase 1, a Product of Differentiated Colon Epithelial Cells, Can Partially Replace Glycoprotein 91phox in the Regulated Production of Superoxide by Phagocytes , 2003, The Journal of Immunology.

[19]  S. Bilke,et al.  Proteomic expression profiling of thyroid neoplasms , 2007, Proteomics. Clinical applications.

[20]  Peter Houghton,et al.  Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. , 2007, Cancer research.